Cost-effectiveness of long-acting cabotegravir/rilpivirine for people with HIV and adherence challenges at the Ward 86 clinic: an intermediate outcome analysis
Initiating CAB/RPV-LA for PWH with viremia suggests highly favorable cost-effectiveness. Results are sensitive to the costs of antiretroviral drugs, but not to variations in personnel costs or rates of viral suppression within plausible input ranges.
Authors
- Francis Mayorga‐Munoz
- Matthew D. Hickey (ORCID: https://orcid.org/0000-0001-8913-1602)
- Ryan W. Walker (ORCID: https://orcid.org/0000-0001-8748-0913)
- Elliot Marseille (ORCID: https://orcid.org/0000-0001-8518-1143)
- John D. Szumowski (ORCID: https://orcid.org/0000-0002-0287-9704)
- Monica Gandhi (ORCID: https://orcid.org/0000-0002-7025-1994)
- Mary Shiels
- Elizabeth Imbert (ORCID: https://orcid.org/0000-0002-3060-3596)
- Janet R. Grochowski (ORCID: https://orcid.org/0000-0002-9816-7073)
- Tor Neilands
- Mallory O. Johnson (ORCID: https://orcid.org/0000-0003-0480-2804)
- Katerina A. Christopoulos (ORCID: https://orcid.org/0000-0002-8598-2191)
- Jon Oskarsson
Institutions
- San Francisco General Hospital (US)
- University of California, San Francisco (US)
- Health Strat (Kenya) (KE)
- San Francisco VA Health Care System (US)
- Columbia College (CA)
- Royal College of Physicians (GB)
- Columbia University (US)
Publication Details
- Journal
- AIDS
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1097/qad.0000000000004145
- Citations
- 1
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 1.40